|会社名||Gilead Sciences Inc （ギリアド・サイエンシズ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 ギリアド・サイエンシズ（Gilead Sciences Inc.）は医薬品の発見・開発・商業化を行う研究型バイオ医薬品会社である。同社の製品ポートフォリオと治験薬のパイプラインはヒト免疫不全ウイルス、後天性免疫不全症候群（HIV/AIDS）、肝疾患、癌、炎症、呼吸器疾患、心血管疾患を含む。HIV/AIDS患者用製品は「Descovy」、「Odefsey」、「Genvoya」、「Stribild」、「Complera」、「Eviplera」、「Truvada」、「Emtriva」、「Tybost」、「Vitekta｣を含む。肝臓疾患患者用製品は「Vemlidy」、「Epclusa」、「Harvoni」、「Sovaldi」、「Viread」、「Hepsera｣を含む。同社は血液学・腫瘍疾患の患者にZydeligを提供する。心臓血管疾患の患者用製品は「Letairis」、「Ranexa」、「Lexiscan｣を含む。炎症・呼吸器疾患治療用の製品は「Cayston」と「Tamiflu」を含む。 ギリアド・サイエンシズは米国の医薬品会社。主要製品は抗HIV薬の｢ツルバダ｣、｢アトリプラ｣、B型肝炎治療薬｢ヘプセラ｣、｢ビリア―ド｣、侵襲性真菌感染症治療薬｢アンビゾ―ム｣、肺動脈高血圧症治療薬｢レタイリス｣、サイトメガロウイルス性網膜炎治療薬｢ビスタイド｣、慢性狭心症治療薬｢ラネクサ｣など。本社はカリフォルニア州。 Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.|
|本社所在地||333 Lakeside Drive Foster City CA 94404 USA|
|代表者氏名||John C. Martin ジョンC.マーティン|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Gilead Sciences Inc. revenues decreased 21% to $10.74B. Net income before extraordinary items decreased 42% to $3.35B. Revenues reflect Antiviral products segment decrease of 26% to $9.14B. Net income also reflects Research and development expenses increase of 19% to $2.13B (expense) Selling general and administrative expe increase of 13% to $1.98B (expense).|
A biotech VC accuses his Proskauer lawyers of bungling a hedge fund deal, costing him 'hundreds of millions' 2021/05/04 17:15:16 Business Insider
Summary List Placement A life sciences venture capitalist claims he was shut out of the meteoric rise of his former partner's hedge fund because his ex-lawyers at Proskauer Rose bungled the deal. Dr. Robert Adelman, the managing partner of venBio, says he missed out on the success of Avoro Capital, a hedge fund spun out of venBio in 2016. Lawyers at Proskauer made a drafting error in fund documents that forced him to sell his Avoro stake in 2019, Adelman alleges. His state-court lawsuit against the Big Law firm hasn't previously been reported. Avoro was up 19.5% for the year through last August and grew 60% in 2019, the year Adelman was pushed out, according to Institutional Investor . One of its top holdings was Immunomedics Inc., which was purchased by Gilead Sciences last year for $21 billion, generating huge profits for Avoro. Proskauer's terms gave Behzad Aghazadeh, the hedge fund's managing partner, the authority to declare a "strategic transaction" that would result in the redemption of Adelman's 27.5% stake in the fund, according to the March 2020 lawsuit.
GOLDMAN SACHS: Buy these 24 high-growth stocks that are investing in cash cows for the future at the highest rates in the S&P 500 2021/05/04 14:54:00 Business Insider
Summary List Placement Investing in growth stocks can be a difficult game at the moment. Many have unthinkably high valuations thanks to things like low interest rates and heightened speculation, raising questions about how long their outperformance can last going forward. On the other hand, investing solely based on valuation isn't always necessarily the best approach either. Another way to identify companies that could do well in the future is by looking at how much they're investing in themselves and planting the seeds of future growth. In a recent note, a team of analysts at Goldman Sachs did just that, and came up with a list of firms outperforming the S&P 500 average in terms of investment for the future. To do so, they looked at how much a firm is investing in the future as a percentage of their operating cash flow while also factoring in asset depreciation. "High capex spending by itself can be a flawed measure of investment for future growth since many firms operate in asset-heavy industries and may barely invest at a rate faster than assets are depreciating," Goldman's Chief US Equity Strategist David Kostin said in the Monday note.
Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings 2021/04/30 11:39:41 Benzinga
Gilead Sciences Inc (NASDAQ: GILD ) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Sales of $6.42 billion missed the consensus of $6.74 billion but grew 16% Y/Y. Revenue … Full story available on Benzinga.com
Gilead first-quarter profit rises despite lower HIV drug sales 2021/04/29 20:40:36 Investing.com
Gilead Earnings Beat, Revenue Misses In Q1 2021/04/29 20:09:50 Investing.com
Pfizer begins early-stage study of oral drug to combat coronavirus 2021/03/23 17:08:56 Economic Times India
Pfizer Inc has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on Tuesday. The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SA, said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies. Pfizer's candidate, named PF-07321332, is a protease inhibitor that prevents the virus from replicating in cells. Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both on their own and in combination with other antivirals, the company said. Pfizer believes this class of molecules may provide well-tolerated treatments against COVID-19, as currently marketed therapeutics that work on the same lines have not reported safety concerns. The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients. "Together, the two (oral and intravenous candidates) have the potential to create an end-to-end treatment paradigm that complements vaccination in cases where disease still occurs," Pfizer's Chief Medical Officer Mikael Dolsten said in a statement.
Hulu April 2021: Every new movie and show coming this month - CNET 2021/03/19 13:51:00 CNET
We return to Gilead with the fourth season of The Handmaid's Tale, and go hunting for Bigfoot.
Gilead and Novo Nordisk advance NASH collaboration to larger clinical study - MedCity News 2021/03/18 21:21:57 MedCity News
Clinical tests of drugs from Gilead Sciences and Novo Nordisk have yielded encouraging results in nonalcoholic steatohepatitis (NASH), and the partners now want to see if the drug combinations help patients in a larger mid-stage study. The planned Phase 2b study expands on a 2019 R&D alliance.
Gilead, Novo Nordisk Expand NASH Collaboration 2021/03/18 13:16:56 TipRanks
Gilead and Novo Nordisk are expanding their clinical collaboration for non-alcoholic steatohepatitis (NASH). Shares of Gilead, a biopharmaceutical company, are down ab…
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ギリアド・サイエンシズ GILD Gilead Sciences Inc.）